Trial · NCT00006305
Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes
NCT00006305, Phase 3, Completed, University of Pittsburgh; results first posted 2011-05-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes. Trials, record NCT00006305. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00006305
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes
- NCT number
- NCT00006305
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 2,368 participants, actual
- Lead sponsor
- University of Pittsburgh
- Conditions
- Coronary Disease, Cardiovascular Diseases, Heart Diseases, Insulin Resistance, Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions, Coronary Artery Bypass, Biguanides, thiazolidinediones, Insulin, sulfonylurea, ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
- First posted
- 2000-09-29
- Last updated
- 2016-02-08
- Results first posted
- 2011-05-12
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With All-Cause Mortality | five years | |
| Secondary | Number of Participants With Death, Myocardial Infarction, or Stroke | five years |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With All-Cause Mortality | five years | Intention to treat analysis (ITT) of the two main effects in the 2x2 factorial design, 1) Revascularization versus Medical Therapy and 2) Insulin Sensitizing (IS) versus Insulin Providing (IP) | participants | NUMBER |
| SECONDARY | Number of Participants With Death, Myocardial Infarction, or Stroke | five years | Intention to treat analysis (ITT) of the two main effects in the 2x2 factorial design, 1) Revascularization versus Medical Therapy and 2) Insulin Sensitizing (IS) versus Insulin Providing (IP) | participants | NUMBER |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With All-Cause Mortality | Revascularization and Insulin Providing (IP) | 80 | participants | ||
| Number of Participants With All-Cause Mortality | Revascularization and Insulin Sensitizing (IS) | 75 | participants | ||
| Number of Participants With All-Cause Mortality | Medical Therapy and Insulin Providing (IP) | 80 | participants | ||
| Number of Participants With All-Cause Mortality | Medical Therapy and Insulin Sensitizing (IS) | 81 | participants | ||
| Number of Participants With Death, Myocardial Infarction, or Stroke | Revascularization and Insulin Providing (IP) | 145 | participants | ||
| Number of Participants With Death, Myocardial Infarction, or Stroke | Revascularization and Insulin Sensitizing (IS) | 121 | participants | ||
| Number of Participants With Death, Myocardial Infarction, or Stroke | Medical Therapy and Insulin Providing (IP) | 143 | participants | ||
| Number of Participants With Death, Myocardial Infarction, or Stroke | Medical Therapy and Insulin Sensitizing (IS) | 140 | participants |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Revascularization and Insulin Providing (IP) | 592 | |
| Overall Study | STARTED | Revascularization and Insulin Sensitizing (IS) | 584 | |
| Overall Study | STARTED | Medical Therapy and Insulin Providing (IP) | 593 | |
| Overall Study | STARTED | Medical Therapy and Insulin Sensitizing (IS) | 599 | |
| Overall Study | COMPLETED | Revascularization and Insulin Providing (IP) | 575 | |
| Overall Study | COMPLETED | Revascularization and Insulin Sensitizing (IS) | 574 | |
| Overall Study | COMPLETED | Medical Therapy and Insulin Providing (IP) | 578 | |
| Overall Study | COMPLETED | Medical Therapy and Insulin Sensitizing (IS) | 585 | |
| Overall Study | NOT COMPLETED | Revascularization and Insulin Providing (IP) | 17 | |
| Overall Study | NOT COMPLETED | Revascularization and Insulin Sensitizing (IS) | 10 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events36
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pitting Edema | General disorders | Revascularization and Insulin Providing (IP) | 293 | 592 | |
| other | Pitting Edema | General disorders | Revascularization and Insulin Sensitizing (IS) | 317 | 584 | |
| other | Pitting Edema | General disorders | Medical Therapy and Insulin Providing (IP) | 304 | 593 | |
| other | Pitting Edema | General disorders | Medical Therapy and Insulin Sensitizing (IS) | 335 | 599 | |
| other | Bone Fracture | Musculoskeletal and connective tissue disorders | Revascularization and Insulin Providing (IP) | 38 | 592 | |
| other | Bone Fracture | Musculoskeletal and connective tissue disorders | Revascularization and Insulin Sensitizing (IS) | 48 | 584 | |
| other | Bone Fracture | Musculoskeletal and connective tissue disorders | Medical Therapy and Insulin Providing (IP) | 36 | 593 | |
| other | Bone Fracture | Musculoskeletal and connective tissue disorders | Medical Therapy and Insulin Sensitizing (IS) | 34 | 599 | |
| other | Laser Therapy for Macular Edema | Eye disorders | Revascularization and Insulin Providing (IP) | 47 | 592 | |
| other | Laser Therapy for Macular Edema | Eye disorders | Revascularization and Insulin Sensitizing (IS) | 42 | 584 |
1 to 10 of 36Source ClinicalTrials.gov
See all 36 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Revascularization and Insulin Providing (IP) | ||
| Total, all-cause mortality | Revascularization and Insulin Sensitizing (IS) | ||
| Total, all-cause mortality | Medical Therapy and Insulin Providing (IP) | ||
| Total, all-cause mortality | Medical Therapy and Insulin Sensitizing (IS) | ||
| Total, other adverse events | Revascularization and Insulin Providing (IP) | 331 | 592 |
| Total, other adverse events | Revascularization and Insulin Sensitizing (IS) | 362 | 584 |
| Total, other adverse events | Medical Therapy and Insulin Providing (IP) | 344 | 593 |
| Total, other adverse events | Medical Therapy and Insulin Sensitizing (IS) | 363 | 599 |
| Total, serious adverse events | Revascularization and Insulin Providing (IP) | 230 | 592 |
| Total, serious adverse events | Revascularization and Insulin Sensitizing (IS) | 210 | 584 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers52
The papers the trial lists on ClinicalTrials.gov.
Grants4
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| U01HL061744 | BARI II: A TRIAL OF REVASC. & GLYCEMIC CONTROL IN NIDDM | KELSEY, SHERYL F | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2000 to 2009 | NIH RePORTER |
| U01HL061746 | BARI II GRANT PROPOSAL FOR ECG CORE LABORATORY | CHAITMAN, BERNARD R | SAINT LOUIS UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2000 to 2008 | NIH RePORTER |
| U01HL061748 | ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2 | HLATKY, MARK A. | STANFORD UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2000 to 2006 | NIH RePORTER |
| U01HL063804 | BARI II - FIBRINOLYSIS AND COAGULATION CORE | SOBEL, BURTON E | UNIVERSITY OF VERMONT & ST AGRIC COLLEGE | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2000 to 2006 | NIH RePORTER |
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00006305
GET https://conductscience.org/api/trials/v1/NCT00006305/events?page=2